Peran SGLT2i terhadap Risiko Kardiorenal Pasien dengan atau Tanpa Diabetes Melitus Tipe 2
DOI:
https://doi.org/10.55175/cdk.v51i2.873Keywords:
Diabetes mellitus, kidney, heart, SGLT2iAbstract
Sodium-glucose Co-transporter 2 inhibitor (SGLT2i) is one of the antidiabetic classes recommended for patients with heart and kidney problems. Evidence-based studies show the benefits of SGLT2i extend to heart, kidney, or other metabolic diseases in patients without diabetes mellitus.
Downloads
References
Soelistijo SA, Suastika K, Lindarto D, Decroli E, Permana H, Sucipto KW, et al. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2021. Jakarta: PB Perkeni, 2021.
IDF Diabetes Atlas. Indonesia Diabetes Report 2000 — 2045 [Internet]. 2022 [cited 2022 Aug 10]. Available from: https://diabetesatlas.org/data/en/country/94/id.html
Elsayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes—2023. Diabetes Care. 2023;46(suppl):S140–57.
Fernandez-Fernandez B, Sarafidis P, Kanbay M, Navarro-González JF, Soler MJ, Górriz JL, et al. SGLT2 inhibitors for non-diabetic kidney disease: Drugs to treat CKD that also improve glycaemia. Clin Kidney J. 2020; 13:728–33.
Teo YH, Teo YN, Syn NL, Kow CS, Yoong CSY, Tan BYQ, et al. Effects of sodium/glucose cotransporter 2 (Sglt2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: A systematic review and meta-analysis of randomized-controlled trials. J Am Heart Assoc. 2021;10(5):1–18.
Tortora GJ, Derrickson B. Principles of human anatomy & physiology. 12th ed. United States: John Wiley & Sons, Inc.; 2009.
DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11–26.
Liu H, Sridhar VS, Boulet J, Dharia A, Khan A, Lawler PR, et al. Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: From biomarkers to clinical outcomes in heart failure and diabetic kidney disease. Metabolism: Clinical and Experimental. 2022; 126:154918. DOI: 10.1016/j.metabol.2021.154918
Storgaard H, Gluud LL, Bennett C, Grøndahl MF, Christensen MB, Knop FK, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: A systematic review and meta-analysis. PLoS One. 2016;11(11): e0166125.
Farxiga (Dapagliflozin) highlights of prescribing information. Wilmington: AstraZeneca Pharmaceuticals LP; 2021.
Jardiance (Empagliflozin) highlights of prescribing information. Ridgefield: Boehringer Ingelheim Pharmaceuticals, Inc; 2021.
Invokana (Canagliflozin) highlights of prescribing information. Titusville: Janssen Pharmaceuticals, Inc; 2022.
Steglatro (Ertugliflozin) highlights of prescribing information. Whitehouse Station: Merck & Co., Inc.; 2017.
Food and Drug Administration. FDA drug safety communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density [Internet]. 2015 [cited 2022 Nov 27]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet
Ku EJ, Lee DH, Jeon HJ, Oh TK. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study. Diabetes Res Clin Pract. 2019;151:65–73.
Hussain M, Atif M, Babar M, Akhtar L. Comparison of efficacy and safety profile of empaglifozin versus dapaglifozin as add on therapy in type 2 diabetic patients. J Ayub Med Coll Abbottabad. 2021;33(4).
Yang AY, Chen HC. Comparative assessment of the long-term effectiveness and safety of dapagliflozin and empagliflozin as add-on therapy to hypoglycemic drugs in patients with type 2 diabetes. J Diabetes Res. 2022;2022.
Nakagaito M, Joho S, Ushijima R, Nakamura M, Kinugawa K. Comparison of canagliflozin, dapagliflozin and empagliflozin added to heart failure treatment in decompensated heart failure patients with type 2 diabetes mellitus. Circ Rep. 2019;1(10):405–13.
Tager T, Atar D, Agewall S, Katus HA, Grundtvig M, Cleland JGF, et al. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials. Heart Failure Rev. 2021;16:1421–35.
Memon RA, Akbariromani H, Vohra RR, Kundi H, Saleem RF, Ghaffari M Abuzar, et al. Comparison of cardiovascular outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes: A meta-analysis. Cureus. 2022;14(7):e27277.
Lim J, Hwang IC, Choi HM, Yoon YE, Cho GY. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease. PLoS One 2022;17(10): e0269414.
Shao SC, Chang KC, Lin SJ, Chang SH, Hung MJ, Chan YY, et al. Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: Effect modification by atherosclerotic cardiovascular disease. Cardiovasc Diabetol. 2021;20(1).
Hao Z, Zhang Y. Dapagliflozin and empagliflozin in heart failure with reduced ejection fraction: A retrospective study. Int J Gen Med. 2022;15:5915–8.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24.
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98.
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.
The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–27.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Allen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
